ArticleNeurourology and urodynamics2015
Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.
Article in Neurourology and urodynamics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders.International urology and nephrology · 2022Pooled it
- Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.The Journal of urology · 2017Pooled it
- Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.The Journal of urology · 2022Trial
- Mechanosensitive release of ATP in the urinary bladder mucosa.Purinergic signalling · 2025Review
- Advancements in the management of overactive bladder in women using nano-botulinum toxin type A: A narrative review.Current urology · 2025Review
- Article
- Ultrasound-assisted intravesical botulinum toxin A delivery attenuates acetic acid-induced bladder hyperactivity in rats.Frontiers in pharmacology · 2023Article
- Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients-Preliminary Results.Toxins · 2022Article
- Nano-BTA: A New Strategy for Intravesical Delivery of Botulinum Toxin A.International neurourology journal · 2022Article
- Review
- Purinergic signalling in the urinary bladder - When function becomes dysfunction.Autonomic neuroscience : basic & clinical · 2021Article
- Contractile and Structural Properties of Detrusor from Children with Neurogenic Lower Urinary Tract Dysfunction.Biology · 2021Article
- The Potential of Asiatic Acid in the Reversion of Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats.International journal of molecular sciences · 2021Article
- The Urothelium: Life in a Liquid Environment.Physiological reviews · 2020Review
- Review
- Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.Toxins · 2020Review
- Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.Toxins · 2020Review
- Review
- Asiatic Acid, a Natural Compound that Exerts Beneficial Effects on the Cystometric and Biochemical Parameters in the Retinyl Acetate-Induced Model of Detrusor Overactivity.Frontiers in pharmacology · 2020Article
- Purinergic receptor mediated calcium signalling in urothelial cells.Scientific reports · 2019Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
aimsBotulinum neurotoxin serotype A (BoNT/A) has emerged as an effective treatment of urinary bladder overactivity. Intravesical lipotoxin (BoNT/A delivery using liposomes), which may target the urothelium, is effective in blocking acetic acid induced hyperactivity in animals. The objective of this study was to assess the possible site of toxin action within the urothelium.
methodsWe examined expression of the toxin receptor (SV2) and its cleavage targets (SNAP-25 and SNAP-23) within urothelium as well as effects of the toxin on mechanically evoked release of ATP from cultured rat urothelial cells. ATP release was measured using the luciferin-luciferase assay; we examined expression of SNAP-23 and -25 in urothelial cells and mucosa of rat and human bladders.
resultsBoNT/A (1.5 U; 1-3 hr) blocked hypotonic evoked release of urothelial ATP, without affecting morphology. The expression of protein targets for BoNT/A binding (SV2) was detected in human and rat bladder mucosa and catalytic action (SNAP-23, -25) in urothelial cells and mucosa (differed in intensity) from rat and human bladder. Incubation of cultured (rat) urothelial cells with BoNT/A decreased expression levels of both SNAP-23 (44%) and SNAP-25 (80%).
conclusionsOur findings reveal that the bladder urothelium expresses the intracellular targets and the binding protein for cellular uptake of BoNT/A; and that the toxin is able to suppress the levels of these targets as well as hypotonic-evoked ATP release. These data raise the possibility that intravesical treatment with BoNT/A suppresses bladder reflex and sensory mechanisms by affecting a number of urothelial functions including release of transmitters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.